(DGX) Quest Diagnostics - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US74834L1008
Stock: Diagnostic Testing, Clinical Labs, Pathology Reports, Risk Assessment, Health IT
Total Rating 55
Risk 90
Buy Signal -0.62
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.84% |
| Yield on Cost 5y | 2.92% |
| Yield CAGR 5y | 6.81% |
| Payout Consistency | 98.5% |
| Payout Ratio | 33.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.6% |
| Relative Tail Risk | -11.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.71 |
| Alpha | 11.13 |
| Character TTM | |
|---|---|
| Beta | 0.225 |
| Beta Downside | 0.165 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.60% |
| CAGR/Max DD | 0.68 |
Description: DGX Quest Diagnostics December 19, 2025
Quest Diagnostics (NYSE:DGX) is a leading provider of diagnostic testing and related information services in the U.S. and abroad, operating under the Quest brand and several specialty brands (AmeriPath, Dermpath, ExamOne, Quanum). Its offerings span routine to advanced clinical and anatomic pathology tests, risk-assessment solutions for insurers, and health-IT platforms, delivered through a nationwide network of labs, patient service centers, mobile phlebotomists, and call centers.
Key operating metrics (FY 2023) include approximately **$12.6 billion in revenue**, a **~9 % operating margin**, and a **~5 % year-over-year growth in specialty-testing volumes**, driven by rising demand for genetic and oncology panels. The business is sensitive to **Medicare/Medicaid reimbursement policies**, **aging demographics**, and the broader **shift toward value-based care**, which fuels demand for integrated diagnostics and population-health analytics.
For a deeper quantitative assessment of DGX’s valuation and risk profile, you may find ValueRay’s analyst tools helpful for further research.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 969.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.24 > 1.0 |
| NWC/Revenue: 2.52% < 20% (prev 5.57%; Δ -3.05% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.89b > Net Income 969.0m |
| Net Debt (5.95b) to EBITDA (2.14b): 2.78 < 3 |
| Current Ratio: 1.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 33.30% > 18% (prev 0.33%; Δ 3297 % > 0.5%) |
| Asset Turnover: 67.20% > 50% (prev 59.27%; Δ 7.93% > 0%) |
| Interest Coverage Ratio: 5.60 > 6 (EBITDA TTM 2.14b / Interest Expense TTM 282.0m) |
Altman Z'' 3.91
| A: 0.02 (Total Current Assets 2.41b - Total Current Liabilities 2.13b) / Total Assets 16.20b |
| B: 0.61 (Retained Earnings 9.84b / Total Assets 16.20b) |
| C: 0.10 (EBIT TTM 1.58b / Avg Total Assets 16.15b) |
| D: 1.11 (Book Value of Equity 9.80b / Total Liabilities 8.82b) |
| Altman-Z'' Score: 3.91 = AA |
Beneish M -3.05
| DSRI: 0.93 (Receivables 1.46b/1.38b, Revenue 10.85b/9.54b) |
| GMI: 0.98 (GM 33.30% / 32.77%) |
| AQI: 1.02 (AQ_t 0.68 / AQ_t-1 0.67) |
| SGI: 1.14 (Revenue 10.85b / 9.54b) |
| TATA: -0.06 (NI 969.0m - CFO 1.89b) / TA 16.20b) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of DGX shares?
As of February 07, 2026, the stock is trading at USD 190.71 with a total of 1,099,521 shares traded.
Over the past week, the price has changed by +1.97%, over one month by +6.16%, over three months by +8.54% and over the past year by +19.44%.
Over the past week, the price has changed by +1.97%, over one month by +6.16%, over three months by +8.54% and over the past year by +19.44%.
Is DGX a buy, sell or hold?
Quest Diagnostics has received a consensus analysts rating of 3.89.
Therefore, it is recommended to buy DGX.
- StrongBuy: 8
- Buy: 1
- Hold: 10
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DGX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 199.3 | 4.5% |
| Analysts Target Price | 199.3 | 4.5% |
| ValueRay Target Price | 213.1 | 11.7% |
DGX Fundamental Data Overview February 01, 2026
P/E Trailing = 21.4238
P/E Forward = 17.331
P/S = 1.9276
P/B = 2.7949
P/EG = 1.469
Revenue TTM = 10.85b USD
EBIT TTM = 1.58b USD
EBITDA TTM = 2.14b USD
Long Term Debt = 5.17b USD (from longTermDebt, last quarter)
Short Term Debt = 677.0m USD (from shortTermDebt, last quarter)
Debt = 6.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.95b USD (from netDebt column, last quarter)
Enterprise Value = 26.86b USD (20.91b + Debt 6.38b - CCE 432.0m)
Interest Coverage Ratio = 5.60 (Ebit TTM 1.58b / Interest Expense TTM 282.0m)
EV/FCF = 19.29x (Enterprise Value 26.86b / FCF TTM 1.39b)
FCF Yield = 5.19% (FCF TTM 1.39b / Enterprise Value 26.86b)
FCF Margin = 12.84% (FCF TTM 1.39b / Revenue TTM 10.85b)
Net Margin = 8.93% (Net Income TTM 969.0m / Revenue TTM 10.85b)
Gross Margin = 33.30% ((Revenue TTM 10.85b - Cost of Revenue TTM 7.24b) / Revenue TTM)
Gross Margin QoQ = 33.70% (prev 34.15%)
Tobins Q-Ratio = 1.66 (Enterprise Value 26.86b / Total Assets 16.20b)
Interest Expense / Debt = 1.08% (Interest Expense 69.0m / Debt 6.38b)
Taxrate = 22.92% (77.0m / 336.0m)
NOPAT = 1.22b (EBIT 1.58b * (1 - 22.92%))
Current Ratio = 1.13 (Total Current Assets 2.41b / Total Current Liabilities 2.13b)
Debt / Equity = 0.88 (Debt 6.38b / totalStockholderEquity, last quarter 7.26b)
Debt / EBITDA = 2.78 (Net Debt 5.95b / EBITDA 2.14b)
Debt / FCF = 4.27 (Net Debt 5.95b / FCF TTM 1.39b)
Total Stockholder Equity = 7.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.00% (Net Income 969.0m / Total Assets 16.20b)
RoE = 13.75% (Net Income TTM 969.0m / Total Stockholder Equity 7.05b)
RoCE = 12.91% (EBIT 1.58b / Capital Employed (Equity 7.05b + L.T.Debt 5.17b))
RoIC = 9.40% (NOPAT 1.22b / Invested Capital 12.94b)
WACC = 5.36% (E(20.91b)/V(27.30b) * Re(6.74%) + D(6.38b)/V(27.30b) * Rd(1.08%) * (1-Tc(0.23)))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 86.58% ; FCFF base≈1.25b ; Y1≈1.28b ; Y5≈1.42b
Fair Price DCF = 326.2 (EV 42.24b - Net Debt 5.95b = Equity 36.29b / Shares 111.2m; r=5.90% [WACC]; 5y FCF grow 2.43% → 2.90% )
EPS Correlation: -41.92 | EPS CAGR: -51.61% | SUE: -4.0 | # QB: 0
Revenue Correlation: 30.38 | Revenue CAGR: 0.69% | SUE: 3.44 | # QB: 2
EPS next Quarter (2026-03-31): EPS=2.37 | Chg30d=+0.009 | Revisions Net=+2 | Analysts=12
EPS next Year (2026-12-31): EPS=10.42 | Chg30d=+0.040 | Revisions Net=+3 | Growth EPS=+6.2% | Growth Revenue=+3.6%
P/E Forward = 17.331
P/S = 1.9276
P/B = 2.7949
P/EG = 1.469
Revenue TTM = 10.85b USD
EBIT TTM = 1.58b USD
EBITDA TTM = 2.14b USD
Long Term Debt = 5.17b USD (from longTermDebt, last quarter)
Short Term Debt = 677.0m USD (from shortTermDebt, last quarter)
Debt = 6.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.95b USD (from netDebt column, last quarter)
Enterprise Value = 26.86b USD (20.91b + Debt 6.38b - CCE 432.0m)
Interest Coverage Ratio = 5.60 (Ebit TTM 1.58b / Interest Expense TTM 282.0m)
EV/FCF = 19.29x (Enterprise Value 26.86b / FCF TTM 1.39b)
FCF Yield = 5.19% (FCF TTM 1.39b / Enterprise Value 26.86b)
FCF Margin = 12.84% (FCF TTM 1.39b / Revenue TTM 10.85b)
Net Margin = 8.93% (Net Income TTM 969.0m / Revenue TTM 10.85b)
Gross Margin = 33.30% ((Revenue TTM 10.85b - Cost of Revenue TTM 7.24b) / Revenue TTM)
Gross Margin QoQ = 33.70% (prev 34.15%)
Tobins Q-Ratio = 1.66 (Enterprise Value 26.86b / Total Assets 16.20b)
Interest Expense / Debt = 1.08% (Interest Expense 69.0m / Debt 6.38b)
Taxrate = 22.92% (77.0m / 336.0m)
NOPAT = 1.22b (EBIT 1.58b * (1 - 22.92%))
Current Ratio = 1.13 (Total Current Assets 2.41b / Total Current Liabilities 2.13b)
Debt / Equity = 0.88 (Debt 6.38b / totalStockholderEquity, last quarter 7.26b)
Debt / EBITDA = 2.78 (Net Debt 5.95b / EBITDA 2.14b)
Debt / FCF = 4.27 (Net Debt 5.95b / FCF TTM 1.39b)
Total Stockholder Equity = 7.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.00% (Net Income 969.0m / Total Assets 16.20b)
RoE = 13.75% (Net Income TTM 969.0m / Total Stockholder Equity 7.05b)
RoCE = 12.91% (EBIT 1.58b / Capital Employed (Equity 7.05b + L.T.Debt 5.17b))
RoIC = 9.40% (NOPAT 1.22b / Invested Capital 12.94b)
WACC = 5.36% (E(20.91b)/V(27.30b) * Re(6.74%) + D(6.38b)/V(27.30b) * Rd(1.08%) * (1-Tc(0.23)))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 86.58% ; FCFF base≈1.25b ; Y1≈1.28b ; Y5≈1.42b
Fair Price DCF = 326.2 (EV 42.24b - Net Debt 5.95b = Equity 36.29b / Shares 111.2m; r=5.90% [WACC]; 5y FCF grow 2.43% → 2.90% )
EPS Correlation: -41.92 | EPS CAGR: -51.61% | SUE: -4.0 | # QB: 0
Revenue Correlation: 30.38 | Revenue CAGR: 0.69% | SUE: 3.44 | # QB: 2
EPS next Quarter (2026-03-31): EPS=2.37 | Chg30d=+0.009 | Revisions Net=+2 | Analysts=12
EPS next Year (2026-12-31): EPS=10.42 | Chg30d=+0.040 | Revisions Net=+3 | Growth EPS=+6.2% | Growth Revenue=+3.6%